EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost-effectiveness assessment of liquid biopsy for early detection of lung cancer in Brazil

Kátia Marie Senna, Ivan Ricardo Zimmermann, Márcia Gisele Santos da Costa, Bernardo Rangel Tura, José Ronyeryson Dos Santos Evangelista iD, Marisa Santos iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0328631 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Kátia Marie Senna und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre of Technology Assessment in Health, National Institute of Cardiology, Rio de Janeiro, Brazil. Hauptthemen laut MEDLINE: Lung Neoplasms, Cost-Benefit Analysis, Early Detection of Cancer. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Brazilian Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Lung cancer has a low survival rate due to late diagnosis, with most cases detected at advanced stages. Liquid biopsy, a non-invasive alternative to tissue biopsy, has emerged as a potential screening tool for early lung cancer detection. This study evaluates the cost-effectiveness of liquid biopsy screening using an autoantibody test (EarlyCDT-Lung®) in high-risk populations from the perspective of the Brazilian Unified Health System (SUS).

Methods

A decision-analytic model was developed, combining a decision tree and a Markov model to compare two strategies: standard clinical diagnosis without screening and liquid biopsy screening followed by confirmatory diagnostics. Model inputs included test accuracy, treatment costs, and survival data derived from systematic reviews, national registries, and published economic evaluations. The primary outcome was the incremental cost-effectiveness ratio (ICER) per quality-adjusted life year (QALY). Sensitivity analyses assessed model robustness.

Results

Liquid biopsy screening analysis of a hypothetical cohort of 1,000 individuals at high-risk of lung cancer resulted in an incremental cost of $ 570,120 and an incremental effectiveness of 7.56 QALYs, with an ICER of $ 75,435.63 per QALY gained. This result has far exceeded the willingness-to-pay threshold in Brazil ($ 7,017.54–21,052.62/QALY). Therefore, in case of assuming no significant cost reductions or accuracy improvements, the strategy would only become cost-effective in contexts where lung cancer prevalence exceeds 4.0%. Probabilistic sensitivity analysis confirmed a low likelihood of cost-effectiveness, even with varying test sensitivity, lung cancer prevalence, and cost assumptions.

Discussion

The adoption of an autoantibody test as a liquid biopsy for early lung cancer screening in high-risk populations in Brazil led to increased costs and was not considered cost-effective under the thresholds commonly applied in the Brazilian context.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCost-Benefit AnalysisEarly Detection of CancerHumansBrazilLiquid BiopsyQuality-Adjusted Life YearsMarkov ChainsMaleFemaleDecision TreesMiddle Aged

Autor:innen und Institutionen

  • Centre of Technology Assessment in Health, National Institute of Cardiology, Rio de Janeiro, Brazil.

ORCID-Profile: José Ronyeryson Dos Santos Evangelista, Marisa Santos

Förderung

  • Brazilian Ministry of Health

Zitieren

APA

Senna, K. M., Zimmermann, I. R., Costa, M. G. S. D., Tura, B. R., Evangelista, J. R. D. S., & Santos, M. (2025). Cost-effectiveness assessment of liquid biopsy for early detection of lung cancer in Brazil. PLOS One. https://doi.org/10.1371/journal.pone.0328631

Vancouver

Senna KM, Zimmermann IR, Costa MGSD, Tura BR, Evangelista JRDS, Santos M. Cost-effectiveness assessment of liquid biopsy for early detection of lung cancer in Brazil. PLOS One. 2025. doi:10.1371/journal.pone.0328631

BibTeX
@article{Senna2025,
  author = {Senna, Kátia Marie and Zimmermann, Ivan Ricardo and Costa, Márcia Gisele Santos da and Tura, Bernardo Rangel and Evangelista, José Ronyeryson Dos Santos and Santos, Marisa},
  title = {Cost-effectiveness assessment of liquid biopsy for early detection of lung cancer in Brazil},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0328631}
}
Kostenlos starten →